Objective To explore the relationship between solute carrier protein (SLC) and its receptor chemokine receptor 7 (CCR7) and lymph node micrometastasis in stage I non-small cell lung cancer (NSCLC).Methods 127 patients with stage I NSCLC who were treated in our hospital from January 2019 to March 2020 were selected. They were divided into a control group (n=92) and a metastasis group (n=35), according to the micrometastasis of lymph nodes. All the lesions were removed by radical operation, and then the contents of SLC7A11 and CCR7 in the lesions were detected by immunohistochemistry, and the clinical data, laboratory examination data and imaging examination data of patients were collected. Then logistic regression analysis was used to evaluate the relationship between SLC7A11 and CCR7 and lymph node micrometastasis. Finally, the ROC curve was established to analyze the predictive value of the two and their combined detection for microlymph node metastasis in NSCLC patients. Results The expression levels of SLC7A11 and CCR7 in the two groups were significantly different (P＜0.05). The diameter of lesions, bronchial involvement and TLG in the metastatic group were significantly higher than those in the control group (P＜0.05). The diameter of the lesion (OR=49.254, 95%CI=11.062-507.604) is an independent risk factor affecting the micrometastasis of NSCLC lymph nodes (P＜0.05). The expression levels of SLC7A11 (OR=8.622) and CCR7 (OR=8709) were independent factors affecting the micrometastasis of NSCLC lymph nodes (P＜0.05). SLC7A11, CCR7 and combined diagnosis have good detection value for NSCLC lymph node micrometastasis (all P＜0.05). The specificity of the combined detection was significantly higher than that of SLC7A11 and CCR7 alone (2=7.292, 15.125; both P＜0.01).Conclusion SLC7A11and its receptor CCR7 in the SLC family are significantly associated with micro-lymph node metastasis in NSCLC patients.